Agenda Details | ASGCT Annual Meeting

Detailed Program

Tuesday, May 16 2023
01:30 PM – 03:15 PM PT

Vector-Derived Gene Therapy

This education session will provide an overview of key processes in the development of gene therapy via viral vectors, including LV and AAV. Speakers will highlight translational components of therapy development, i.e., how to move from vector-mediated preclinical studies to gene therapy clinical trials as well as related biologics licensing.

Session Details

01:30 PM – 03:15 PM - Room 403 AB

Co-Chair

Donald B. Kohn, MD. Unversity of California, Los Angeles, Los Angeles, CA

01:30 PM – 03:15 PM - Room 403 AB

Co-Chair

Dan Manning. Spark Therapeutics, PA

01:31 PM – 02:00 PM - Room 403 AB

CMC: Vectors, Cells. What to Know to Leverage Early Phase Studies to Support an Eventual Biologic License Application

Graeme E. Price, PhD. FDA, CBER, OTP, OGT CMC, Silver Spring, MD

02:00 PM – 02:30 PM - Room 403 AB

Overview of Lentiviral Vector Therapies: From Bench to Clinic

John F.. Tisdale, MD. NIH, NHLBI, Bethesda, MD

02:30 PM – 03:00 PM - Room 403 AB

Overview of AAV Gene Therapies: From Bench to Clinic

Allison M.. Bradbury, PhD. Nationwide Children's Hospital; The Ohio State University Wexner Medical ...